Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.

Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However, their use is associated with a significant risk of severe infections, which can be attributed to various factors such as hypogammaglobulinemia, neutropenia, lymphopenia, T-cell exhaustion, cytokine-release syndrome and immune-effector cell-associated neurotoxicity syndrome. As these therapies have been recently approved by regulatory agencies, it is crucial to establish practical guidelines for infection monitoring and prevention until robust data from prospective clinical trials become available. To address this issue, a panel of experienced investigators from the Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT) developed consensus recommendations for mitigating infections associated with CAR T-cell and bispecific antibody therapies in MM patients.

[1]  E. Kastritis,et al.  Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study , 2023, Viruses.

[2]  V. Jiménez‐Yuste,et al.  COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study , 2023, Cancers.

[3]  F. Zhan,et al.  Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis , 2022, Blood advances.

[4]  Meike Schneider,et al.  RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study , 2022, Blood.

[5]  C. Hofmeister,et al.  Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study , 2022, Blood.

[6]  S. Jagannath,et al.  Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies , 2022, Blood.

[7]  J. Goldberg,et al.  Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study , 2022, Blood.

[8]  M. Tomasson,et al.  Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study , 2022, Blood.

[9]  S. Chhabra,et al.  Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma , 2022, JAMA network open.

[10]  Christelle M Colin-Leitzinger,et al.  Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma , 2022, Blood advances.

[11]  B. Vick,et al.  T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals , 2022, Blood.

[12]  Y. Taur,et al.  Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy , 2022, Nature Medicine.

[13]  N. Ledeboer,et al.  Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients , 2022, Cancer Cell.

[14]  L. Vercellino,et al.  Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma , 2022, Bone Marrow Transplantation.

[15]  P. Hari,et al.  Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma , 2021, Blood advances.

[16]  J. Römisch,et al.  SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin , 2021, BioDrugs.

[17]  S. Jagannath,et al.  Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) , 2021, Blood.

[18]  S. Devlin,et al.  Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma , 2021, Blood.

[19]  R. Fonseca,et al.  Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study , 2021, Blood.

[20]  Jianfeng Zhou,et al.  Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy , 2021, Blood Cancer Journal.

[21]  Junnian Zheng,et al.  Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma , 2021, Blood advances.

[22]  Chiung-Yu Huang,et al.  Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy , 2021, Blood advances.

[23]  Boris Katz,et al.  Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study , 2021, Therapeutic advances in hematology.

[24]  S. Jagannath,et al.  Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma , 2021, Cancer Cell.

[25]  S. Harrison,et al.  Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. , 2021, Blood reviews.

[26]  L. Vercellino,et al.  G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma , 2020, Bone Marrow Transplantation.

[27]  S. Seo,et al.  How we prevent infections in patients receiving CD19-targeted chimeric antigen receptor T-cells for B-cell malignancies. , 2020, Blood.

[28]  A. Chari,et al.  B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches , 2020, Leukemia.

[29]  G. Pantaleo,et al.  T‐cell exhaustion in HIV infection , 2019, Immunological reviews.

[30]  L. Fayad,et al.  Safety of CAR T-Cell Therapy in Patients with B-Cell Lymphoma and Chronic Hepatitis B or C Virus Infection. , 2019, Blood.

[31]  S. Almo,et al.  GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells , 2019, Science Translational Medicine.

[32]  J. Fishman,et al.  Inflammatory and Infectious Syndromes Associated with Cancer Immunotherapies. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  F. van Rhee,et al.  Infectious and immunological sequelae of daratumumab in multiple myeloma , 2018, British journal of haematology.

[34]  Hans Anton Schlößer,et al.  Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.

[35]  D. Maloney,et al.  Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. , 2017, Blood.

[36]  Thomas D. Wu,et al.  Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing , 2017, Cancer cell.

[37]  S. Seo,et al.  Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[38]  J. Jang,et al.  Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma , 2015, Transplant infectious disease : an official journal of the Transplantation Society.

[39]  U. Mellqvist,et al.  Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients , 2015, Haematologica.

[40]  S. Harrison,et al.  Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies , 2015, Haematologica.

[41]  E. Wood,et al.  Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications , 2011, Annals of Hematology.

[42]  M. Qazilbash,et al.  Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients , 2011, American journal of hematology.

[43]  R. Bram,et al.  BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells , 2004, The Journal of experimental medicine.

[44]  D. Denning,et al.  Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.